USP24 and lung cancer: Next, we used USP24-i-101 to study the effect of targeting USP24 on drug-resistant EGFRL858R mice with lung cancer induced by gefitinib treatment for a long time (217 days) (Supplementary Fig. 6, Fig. 7E and Fig. 8D).